Combination Therapy of Simeprevir and Sofosbuvir in Recurrent HCV Genotype 4 After Liver Retransplantation: Case Report
Aiman Obed, Anwar Jarrad, Abdalla Bashir, Gero Moog
(Department of Hepatobiliary and Transplant Surgery, Jordan Hospital, Amman, Jordan)
Am J Case Rep 2016; 17:357-359
The treatment of hepatitis C virus (HCV) infection is evolving rapidly. Many studies have been completed during the last 2 years, with more studies still in progress. The management of recurring HCV infection following liver organ transplantation remains very challenging, especially for HCV genotype 4 (GT-4). More research is needed in this area.
CASE REPORT: We report on a patient with a recurring HCV infection and fibrosing cholestatic hepatitis following liver retransplantation, who was successfully treated with a combination therapy of simeprevir and sofosbuvir without interferon/ribavirin. As far as we know, this is the first reported case of this kind.
CONCLUSIONS: This information may be of importance and inform future management of patients with recurrent HCV infections following liver transplantation.
Keywords: Drug Therapy, Combination, Antiviral Agents - therapeutic use, Genotype, Hepacivirus - genetics, Hepatitis C, Chronic - drug therapy, Humans, Liver Transplantation, Male, Middle Aged, Reoperation, Simeprevir - therapeutic use, Sofosbuvir - therapeutic use